Wooly Mammoth startup Colossal seeking at least $20B valuation - Axios

What the report says

Axios reported on July 20, 2026, that Colossal, a startup widely associated with efforts to revive woolly mammoth traits through biotechnology, is seeking a valuation of at least $20 billion. The publicly available source material does not include details on the financing structure, the amount being raised, participating investors, or whether a deal has been finalized.

According to the Axios snippet, the company’s research may have broader relevance beyond de-extinction, including possible applications in pharmaceuticals, climate-related interventions and longevity science. That framing matters because it suggests Colossal is being positioned not only as a high-profile “woolly mammoth” company, but also as a platform for tools and discoveries that could be used across several large scientific and commercial markets.

General context: Colossal Biosciences has become one of the best-known companies in the emerging de-extinction and synthetic biology field. Its public profile has been built around using genetic engineering, reproductive technologies and related biological research to explore whether extinct species’ traits can be recreated in living relatives. Such work has attracted attention from investors, scientists and conservation observers, while also raising questions about feasibility, ethics, ecological impact and how resources should be prioritized.

Because Axios’ full article text was unavailable here, key specifics remain unconfirmed in the supplied evidence, including the company’s current valuation, investor demand, revenue outlook, research milestones and timeline for any potential mammoth-related outcome. The central development is that Colossal is reportedly pursuing a valuation level that would place it among the more highly valued private biotechnology companies.